Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

(2022) Alice B. Gottlieb et al.   ACTA DERMATO-VENEREOLOGICA

Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature

(2022) Mika Yamanaka-Takaichi et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

IL‐17A is a pertinent therapeutic target for moderate to severe hidradenitis suppurativa: combined results from a pre‐clinical and Phase II proof‐of‐concept study

(2022) Alexa B. Kimball et al.   EXPERIMENTAL DERMATOLOGY

Advances in biologic and small molecule therapies for hidradenitis suppurativa

(2022) Stella X. Chen et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

(2021) Sophie Glatt et al.   JAMA Dermatology

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa

(2021) Falk G. Bechara et al.   JAMA Surgery

Drug Survival of Biologics in Patients With Hidradenitis Suppurativa

(2021) Hans Christian Ring et al.   JAMA Dermatology

A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain

(2020) Alice Gottlieb et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Effectiveness of secukinumab in Hidradenitis Suppurativa : an open study (20 cases)

(2020) Z. Reguiaï et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Hidradenitis suppurativa

(2020) Robert Sabat et al.   Nature Reviews Disease Primers

Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System

(2020) Georgios Kokolakis et al.   DERMATOLOGY

High placebo rates in clinical trials: is the problem scoring systems or drug efficacy?

(2020) Alexa B. Kimball   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The epidemiology of hidradenitis suppurativa

(2020) John R. Ingram   BRITISH JOURNAL OF DERMATOLOGY

North American Clinical Management Guidelines for Hidradenitis Suppurativa: a Publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Part II: Topical, Intralesional, and Systemic medical Management

(2019) A. Alikhan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa

(2019) L. Prussick et al.   BRITISH JOURNAL OF DERMATOLOGY

Associations of cutaneous and extra‐cutaneous infections with Hidradenitis Suppurativa in US children and adults

(2019) H. H. Lee et al.   BRITISH JOURNAL OF DERMATOLOGY

Determining the Optimal Dose of Infliximab for Treatment of Hidradenitis Suppurativa

(2019) Ashley N. Oskardmay et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective

(2019) Youwei Bi et al.   AAPS Journal

Evaluating Patients’ Unmet Needs in Hidradenitis Suppurativa: results from the Global VOICE project

(2019) Amit Garg et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease

(2019) Wei-Ti Chen et al.   JAMA Dermatology

Depression and Anxiety in Adults With Hidradenitis Suppurativa

(2019) Myrela O. Machado et al.   JAMA Dermatology

A Comparison of International Management Guidelines for Hidradenitis Suppurativa

(2019) Aleksi J. Hendricks et al.   DERMATOLOGY

Part I. Hidradenitis Suppurativa: Epidemiology, clinical presentation, and pathogenesis

(2019) Samantha R. Goldburg et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report

(2018) L. Thorlacius et al.   BRITISH JOURNAL OF DERMATOLOGY

Profound consequences of hidradenitis suppurativa: a review

(2018) Ł. Matusiak   BRITISH JOURNAL OF DERMATOLOGY

Increased Suicide Risk in Patients with Hidradenitis Suppurativa

(2018) Linnea Thorlacius et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents

(2017) Łukasz Matusiak et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

(2016) Alexa B. Kimball et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa

(2015) G. Kelly et al.   BRITISH JOURNAL OF DERMATOLOGY

Diagnostic delay in hidradenitis suppurativa is a global problem

(2015) D.M. Saunte et al.   BRITISH JOURNAL OF DERMATOLOGY

Pathophysiology of hidradenitis suppurativa: An update

(2015) Errol Prens et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa

(2015) C.C. Zouboulis et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment

(2014) A.B. Kimball et al.   BRITISH JOURNAL OF DERMATOLOGY

Hidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease

(2014) Deirdre Nathalie Dufour et al.   POSTGRADUATE MEDICAL JOURNAL

Painful Hidradenitis Suppurativa

(2010) Howard S. Smith et al.   CLINICAL JOURNAL OF PAIN